Recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors NCT03866382 Conditions Adenocarcinoma, Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, +71 more Locations University of Alabama at Birmingham Cancer Center — Birmingham, Alabama, United States Anchorage Associates in Radiation Medicine — Anchorage, Alaska, United States Anchorage Radiation Therapy Center — Anchorage, Alaska, United States Alaska Breast Care and Surgery LLC — Anchorage, Alaska, United States View all 582 locations View more locations Show fewer locations Loading locations... View Trial Details
Recruiting Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology NCT05756569 Conditions Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma, Female Urogenital Diseases, +22 more Locations Grady Health System — Atlanta, Georgia, United States Emory University Hospital Midtown — Atlanta, Georgia, United States Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia, United States Emory Saint Joseph's Hospital — Atlanta, Georgia, United States View Trial Details
Active, Not Recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors NCT02834013 Conditions Acinar Cell Carcinoma, Adenocarcinoma, Adenocarcinoma of Lung, +207 more Locations University of Alabama at Birmingham Cancer Center — Birmingham, Alabama, United States University of South Alabama Mitchell Cancer Institute — Mobile, Alabama, United States Anchorage Associates in Radiation Medicine — Anchorage, Alaska, United States Anchorage Radiation Therapy Center — Anchorage, Alaska, United States View all 1007 locations View more locations Show fewer locations Loading locations... View Trial Details
